Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sona Nanotech Inc ( (TSE:SONA) ) just unveiled an announcement.
Sona Nanotech Inc. announced that its study on targeted intra-tumoral hyperthermia using biocompatible gold nanorods will be presented at the upcoming Canadian Melanoma Conference. This presentation highlights Sona’s innovative approach to cancer treatment, potentially impacting the industry by providing a safe, effective, and minimally invasive therapy option, which may serve as a valuable adjunct to existing treatments.
More about Sona Nanotech Inc
Sona Nanotech Inc. is engaged in developing a photothermal cancer therapy called Targeted Hyperthermia™ which uses therapeutic heat to treat solid cancer tumors. The therapy involves delivering heat to tumors using infrared light absorbed by gold nanorods, stimulating the immune system, shrinking tumors, inactivating cancer stem cells, and enhancing drug delivery. Sona’s proprietary gold nanorods are CTAB-free, eliminating toxicity risks associated with other technologies. The company also develops diagnostic testing platforms.
YTD Price Performance: 5.77%
Average Trading Volume: 25,677
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$28.46M
For an in-depth examination of SONA stock, go to TipRanks’ Stock Analysis page.